This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of prostate cancer drugs.

This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new protein kinase inhibitor drugs in oncology.

With this report you will be able to track down and foresee activities associated with the development of new treatments for NSCLC.

This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates.

First of its kind, "Antibody Drug Target Atlas in Oncology" provides a comprehensive analysis of the commercialization of antibody drug targets in oncology

This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of melanoma drugs.

This report is written for you to identify your competition and understand which targeting strategies are at work within anti-angiogenic drug development in oncology. It allows you to pin-point which competitors drugs’ clinical out-come may have

This report is written for you to identify your competition and understand which targeting strategies are at work within antibody drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own

This in-depth analysis of the progress of melanoma R&D and current treatment strategies is one of the most extensive reports available in this field.

First in place, BioSeeker has surveyed apoptopic drugs in oncology and identified 119 drug targets, belonging to 114 drugs. This report, The Drug Target Atlas of Apoptopic Drugs in Oncology, is an open landscape of resources to build, fuel, and drive y

Global Cancer Focus Company Directory pulls out virtually all drug developing companies in oncology in the world. After several acquisitions and mergers, BioSeeker offers you the tool to get an updated look on the competitive landscape in oncology, inc

This report aims to analyze the current and future potential of breast cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landsca

This report, Decoding Big Pharma’s R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis.

The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody-based technologies have rapidly developed into one of the major market

In this unique report the hematological cancer pipeline is analyzed and cross referenced by: Investigator,Drug, Sub-indication, Developmental stage, Compound type, Targeted therapy strategy, Target, and Signaling pathway.

Gain insight into the current challenges and commercial opportunities associated with breast cancer therapy.

An update on the most recent advances made for vascular targeting agents that are now entering an exciting stage of development.

Melanoma drug development has and will continue to have a strong focus on target therapy such as vaccines, monoclonal antibodies, dendritic cells, and gene therapy.

In this publication, BioSeeker Group analyzes the latest progress made for 25 drug candidates targeting the cell death pathway, apoptosis. Additionally, more early stage candidates are also under investigation, which brings the total number of compani

BioSeeker Group analyzes the progress made by the large pharmaceutical companies top oncology drug candidates whom has reached Phase III clinical evaluation.

In this newly updated progress analysis, BioSeeker not only provide a solid background and information structure, we also bring the latest within cancer vaccine achievements.

Colorectal cancer (CRC) is the second most common cause of cancer death in much of the developed world. Cancer-related mortality is slowly decreasing as a result of better detection and significant advances in the treatment of advanced colorectal cance

The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeuti

In the report "Leukemia - A Therapeutic & Competitive Insight" BioSeeker does not only describe and analyze the latest years of progress in four different market segments; CLL, CML ALL and AML, but also provide an insight and framework to und

There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 20 years ago. Many of the new classes of agents....

A strategic outlook on protein kinase inhibitors in oncology. Including targets, indictions and competitive assessment.

Superficial bladder cancers (SBC) comprise tumours with low aggressiveness but a high recurrence rate as well as lesions with a high risk of progression.

With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer.

Gain insight into the current challenges and commercial opportunities associated with lymphoma therapy

Research and development in the cancer vaccine field is dominated by its top 10 players, interestingly not including any of the big pharma companies per se. The recent Gardasil approval and GlaxoSmithKline’s acquisition of Corixa will certainly p